LENZ Therapeutics (LENZ) Profit After Tax (2020 - 2026)

LENZ Therapeutics (LENZ) has reported Profit After Tax for 7 consecutive years, with -$41.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 183.8% year-over-year to -$41.5 million; the TTM figure through Mar 2026 stood at -$108.8 million (down 128.14% YoY), while the FY2025 annual figure was -$82.1 million, down 64.92% from the prior year.
• Profit After Tax declined to -$41.5 million in Q1 2026 per LENZ's latest filing, from -$35.8 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$9.6 million in Q3 2024 and bottomed at -$41.5 million in Q1 2026.
• Historically, Profit After Tax has averaged -$20.2 million across 5 years, with a median of -$16.6 million in 2024.
• Annual changes were most pronounced in 2023 — Profit After Tax jumped 50.96% — and 2026, when it tumbled 183.8%.
• LENZ Therapeutics' Profit After Tax stood at -$24.1 million in 2022, then climbed by 1.51% to -$23.7 million in 2023, then jumped by 44.4% to -$13.2 million in 2024, then plunged by 172.23% to -$35.8 million in 2025, then declined by 15.73% to -$41.5 million in 2026.
• Business Quant data shows LENZ's Profit After Tax at -$41.5 million in Q1 2026, -$35.8 million in Q4 2025, and -$16.5 million in Q3 2025.